<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="HCDCCD36603A640D8A1F31641DDB70F16" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>118 HR 5269 IH: Pediatric Network Support Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2023-08-25</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">118th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 5269</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20230825">August 25, 2023</action-date><action-desc><sponsor name-id="C001114">Mr. Curtis</sponsor> (for himself and <cosponsor name-id="T000469">Mr. Tonko</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend the Federal Food, Drug, and Cosmetic Act to provide for the establishment and maintenance of a Pediatric Research Site Network.</official-title></form><legis-body id="HE4D30BD27724430EBC65F58C792F0C32" style="OLC"> 
<section id="HAE8DC3E7F84C4F0C97AD0046DFB7DBBE" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Pediatric Network Support Act</short-title></quote>.</text></section> <section id="H781F7DA091FB4E7D9BB3B82382969150"><enum>2.</enum><header>Pediatric Research Site Network</header><text display-inline="no-display-inline">Subchapter A of chapter V of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/351">21 U.S.C. 351 et seq.</external-xref>) is amended by adding at the end the following:</text> 
<quoted-block style="OLC" id="HD2C9C567607D4FC497B286B21DCF6BAA" display-inline="no-display-inline"> 
<section id="HBA5B49F97907495FA476B85C31CEDD57"><enum>524C.</enum><header>Pediatric Research Site Network</header> 
<subsection id="H432354D7540248EFB3970552F56C282C"><enum>(a)</enum><header>Establishment</header><text>The Secretary shall provide for the establishment and maintenance of a Pediatric Research Site Network in which—</text> <paragraph id="H7ADB5F773C6E4DC3950CA18BF9BE79E6"><enum>(1)</enum><text>the Secretary awards grants to eligible entities; and</text></paragraph> 
<paragraph id="H819670406C0940ADAF2A64A989A1B513"><enum>(2)</enum><text display-inline="yes-display-inline">through such grants, the eligible entities collaborate on—</text> <subparagraph id="HA61D013822DA4BD994A2076DCD0C80E7"><enum>(A)</enum><text>the development and dissemination of guidance and educational materials for the purposes of—</text> 
<clause id="HF9EB8973C70342538010ADC2E134FE51"><enum>(i)</enum><text display-inline="yes-display-inline">enhancing pediatric clinical trials, including with respect to pediatric study design and feasibility;</text></clause> <clause id="HC35D71015608437BB83EA5342CE08196"><enum>(ii)</enum><text>identifying and mitigating challenges in pediatric research that delay pediatric clinical trials;</text></clause> 
<clause id="HC6DFBF69B3A3492387CF7821B37456B7"><enum>(iii)</enum><text display-inline="yes-display-inline">best practices in the conduct of pediatric clinical trials;</text></clause> <clause id="HDE6006A3561F409D88D331FFDCA3A023"><enum>(iv)</enum><text>improving the process for the development of medical products;</text></clause> 
<clause id="H3645696967D64A4FAD6D12D359792222"><enum>(v)</enum><text>labeling innovative medical products;</text></clause> <clause id="H95B01B66EECD462EBCA35269A670BCDA"><enum>(vi)</enum><text>accelerating medical product development; and</text></clause> 
<clause id="H30C639C6BF2846D9B38E2AC8DE4B9679"><enum>(vii)</enum><text>enhancing medical product safety; and</text></clause></subparagraph> <subparagraph id="HA38381C2B53E4FE6913C5F98BDC24B6A"><enum>(B)</enum><text>such other activities as may be determined by the Secretary for purposes of enhancing pediatric clinical trials.</text></subparagraph></paragraph></subsection> 
<subsection id="HDEB6E025C35D4B368E94E56FCCBF60A3"><enum>(b)</enum><header>Eligible entity</header><text>To be eligible to receive a grant under this section, an entity shall meet each of the following:</text> <paragraph id="H5463F887AB4C4CF19596E4AC83AFE6F8"><enum>(1)</enum><text>The entity is—</text> 
<subparagraph id="H2788442E04A547B099C5E59C7BAE7ED1"><enum>(A)</enum><text>an institution of higher education as defined in subsection (a) or (b) of section 101 of the Higher Education Act of 1965; or</text></subparagraph> <subparagraph id="H4BB252F65E164826B229751A90590F18"><enum>(B)</enum><text>an organization described in <external-xref legal-doc="usc" parsable-cite="usc/26/501">section 501(c)(3)</external-xref> of the Internal Revenue Code of 1986 and exempt from tax under section 501(a) of such Code.</text></subparagraph></paragraph> 
<paragraph id="H229B3011729440FAA877B88161E3FF47"><enum>(2)</enum><text>The entity has experienced personnel, and clinical and other technical expertise, in the biomedical sciences.</text></paragraph> <paragraph id="H0992485D0DE6461090FFD12C3AD66067"><enum>(3)</enum><text>The entity demonstrates to the Secretary’s satisfaction that the entity is capable of carrying out the activities described in subsection (a)(2).</text></paragraph></subsection> 
<subsection id="H56A0D57F3686436B984632E9A06A992A"><enum>(c)</enum><header>Annual report</header><text>Not later than 18 months after the date of enactment of this section, and annually thereafter, the Secretary, in collaboration with the grantees under this section, shall submit a report to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives—</text> <paragraph id="H1E58BDBACBAA4C72907A9DE3B3CA517E"><enum>(1)</enum><text display-inline="yes-display-inline">reviewing the operations and activities of the Pediatric Research Site Network in the previous year; and</text></paragraph> 
<paragraph id="HEF385B7DBCCB4BB89BB2908BDA2A294C"><enum>(2)</enum><text>addressing such other issues relating to this section as the Secretary determines to be appropriate.</text></paragraph></subsection> <subsection id="HA77CB146DA4C438FAF4AAB9E8D3EA03E"><enum>(d)</enum><header>Definition</header><text>In this section, the term <term>medical product</term> means a drug (including a biological product), a device (including a diagnostic test), and any combination product described in section 503(g).</text></subsection> 
<subsection id="HCA84566ECECC476A86DF63F218B53A7F"><enum>(e)</enum><header>Authorization of appropriations</header><text>To carry out this section, there is authorized to be appropriated $2,000,000 for each of fiscal years 2024 through 2029.</text></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block></section> </legis-body></bill>

